Table 1 Summary of the clinical characteristics and laboratory data
| Â | PR3-ANCA | MPO-ANCA | P value |
|---|---|---|---|
(N = 9) | (N = 6) | ||
Age | 62.0 (52.0–64.0) | 64.0 (57.5–72.0) | 0.443 |
Sex (male/female) | 5 / 4 | 2 / 4 | 0.608 |
Time | Â | Â | Â |
 from onset to first visit | 12.0 (3.00–22.0) | 28.5 (21.8–43.5) | 0.045 |
 from first visit to treatment | 34.0 (20.0–50.0) | 31.5 (15.0–63.0) | 0.679 |
Department for the first visit (%) | Â | Â | |
 Respiratory medicine | 3 (33 %) | 4 (67 %) | 0.329 |
 Rheumatology | 3 (33 %) | 2 (33 %) |  |
 Nephlorogy | 3 (33 %) | 0 |  |
Labopratory data | Â | Â | Â |
 White Blood Cell (/μL) | 10,600 (8,500–12,000) | 13,750 (13,025–14,400) | 0.099 |
 Neutrophil count (/μL) | 8,578 (6,596–9,434) | 11,721 (11,138–13,132) | 0.077 |
 Lymphocyte count (/μL) | 1,148 (794–1,217) | 795 (737–1,274) | 0.906 |
 Albumin (g/dL) | 3.20 (2.60–3.50) | 3.15 (2.65–3.58) | 1 |
 Creatinine (mg/dL) | 0.70 (0.56–3.34) | 0.64 (0.48–0.78) | 0.48 |
 C-reactive protein (mg/dL) | 8.71 (7.89–9.45) | 14.3 (8.83–16.7) | 0.195 |
 PR3-ANCA | 98.0 (45.0–214) | - | NA |
 MPO-ANCA | - | 61.5 (54.3–83.0) | NA |